Drug Trial Radar · NCT06781281
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Last checked: Nov 19, 2026Latest source record: Jun 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
709
Planned (sponsor's estimate)
Start
Dec 4, 2024
Primary completion
Nov 28, 2026
Study completion Nov 28, 2030
Sponsor
- Lead sponsor
- Henan Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jan 17, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn if serplulimab is effective in early HR+/HER2- breast cancer. This trial serves a prospective parallel control cohort for HELEN-018 (NCT). The main questions it aims to answer are: Does serplulimab combined with neoadjuvant chemotherapy improve the pCR rate of early HR+/HER2- breast cancer? What medical problems do participants have when receiving serplulimab? Researchers will compare the effect of serplulimab combined with chemotherapy to the effect of chemotherapy reported in literature. Participants will: Receive serplulimab plus chemotherapy every 3 weeks for 6 cycles; All patients will receive surgery, and the primary end point is a pathological complete response at the time of definitive surgery; After definitive surgery, the participants will receive adjuvant serplulimab every 3 weeks for up to 6 months from the begining of the treatment.
Conditions
- Breast Cancer Invasive
Interventions
SerplulimabDrug
Serplulimab
NabPEDrug
Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2
Primary outcomes
What the sponsor says the trial is designed to measure.
- pathological complete responseTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan cancer hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.